PMID- 35913555
OWN - NLM
STAT- MEDLINE
DCOM- 20221102
LR  - 20221128
IS  - 2629-3277 (Electronic)
IS  - 2629-3277 (Linking)
VI  - 18
IP  - 8
DP  - 2022 Dec
TI  - Induced Pluripotent Stem Cell-Derived Corneal Cells: Current Status and 
      Application.
PG  - 2817-2832
LID - 10.1007/s12015-022-10435-8 [doi]
AB  - Deficiency and dysfunction of corneal cells leads to the blindness observed in 
      corneal diseases such as limbal stem cell deficiency (LSCD) and bullous 
      keratopathy. Regenerative cell therapies and engineered corneal tissue are 
      promising treatments for these diseases [1]. However, these treatments are not 
      yet clinically feasible due to inadequate cell sources. The discovery of induced 
      pluripotent stem cells (iPSCs) by Shinya Yamanaka has provided a multitude of 
      opportunities in research because iPSCs can be generated from somatic cells, thus 
      providing an autologous and unlimited source for corneal cells. Compared to other 
      stem cell sources such as mesenchymal and embryonic, iPSCs have advantages in 
      differentiation potential and ethical concerns, respectively. Efforts have been 
      made to use iPSCs to model corneal disorders and diseases, drug testing [2], and 
      regenerative medicine [1]. Autologous treatments based on iPSCs can be 
      exorbitantly expensive and time-consuming, but development of stem cell banks 
      with human leukocyte antigen (HLA)- homozygous cell lines can provide cost- and 
      time-efficient allogeneic alternatives. In this review, we discuss the early 
      development of the cornea because protocols differentiating iPSCs toward corneal 
      lineages rely heavily upon recapitulating this development. Differentiation of 
      iPSCs toward corneal cell phenotypes have been analyzed with an emphasis on 
      feeder-free, xeno-free, and well-defined protocols, which have clinical 
      relevance. The application, challenges, and potential of iPSCs in corneal 
      research are also discussed with a focus on hurdles that prevent clinical 
      translation.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Mahmood, Nasif
AU  - Mahmood N
AD  - Department of Textile Engineering, Chemistry, and Science, Wilson College of 
      Textiles, North Carolina State University, Raleigh, NC, 27606, USA.
FAU - Suh, Taylor Cook
AU  - Suh TC
AD  - Department of Textile Engineering, Chemistry, and Science, Wilson College of 
      Textiles, North Carolina State University, Raleigh, NC, 27606, USA.
FAU - Ali, Kiran M
AU  - Ali KM
AD  - Department of Textile Engineering, Chemistry, and Science, Wilson College of 
      Textiles, North Carolina State University, Raleigh, NC, 27606, USA.
FAU - Sefat, Eelya
AU  - Sefat E
AD  - Department of Textile Engineering, Chemistry, and Science, Wilson College of 
      Textiles, North Carolina State University, Raleigh, NC, 27606, USA.
FAU - Jahan, Ummay Mowshome
AU  - Jahan UM
AD  - Department of Textile Engineering, Chemistry, and Science, Wilson College of 
      Textiles, North Carolina State University, Raleigh, NC, 27606, USA.
FAU - Huang, Yihan
AU  - Huang Y
AD  - Department of Textile Engineering, Chemistry, and Science, Wilson College of 
      Textiles, North Carolina State University, Raleigh, NC, 27606, USA.
FAU - Gilger, Brian C
AU  - Gilger BC
AD  - Department of Clinical Sciences, College of Veterinary Medicine, North Carolina 
      State University, Raleigh, NC, 27606, USA.
FAU - Gluck, Jessica M
AU  - Gluck JM
AUID- ORCID: 0000-0002-6908-0809
AD  - Department of Textile Engineering, Chemistry, and Science, Wilson College of 
      Textiles, North Carolina State University, Raleigh, NC, 27606, USA. 
      jmgluck@ncsu.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220801
PL  - United States
TA  - Stem Cell Rev Rep
JT  - Stem cell reviews and reports
JID - 101752767
SB  - IM
MH  - Humans
MH  - *Induced Pluripotent Stem Cells
MH  - Cell Differentiation/genetics
MH  - Cornea
MH  - Cell Line
MH  - *Corneal Diseases/therapy
OTO - NOTNLM
OT  - Cornea
OT  - Corneal tissue engineering
OT  - Differentiation
OT  - Induced pluripotent stem cells
OT  - Limbal stem cell deficiency
EDAT- 2022/08/02 06:00
MHDA- 2022/11/03 06:00
CRDT- 2022/08/01 11:16
PHST- 2022/07/20 00:00 [accepted]
PHST- 2022/08/02 06:00 [pubmed]
PHST- 2022/11/03 06:00 [medline]
PHST- 2022/08/01 11:16 [entrez]
AID - 10.1007/s12015-022-10435-8 [pii]
AID - 10.1007/s12015-022-10435-8 [doi]
PST - ppublish
SO  - Stem Cell Rev Rep. 2022 Dec;18(8):2817-2832. doi: 10.1007/s12015-022-10435-8. 
      Epub 2022 Aug 1.